DEF 14A: Varex Imaging Corporation Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Sentiment:

Proxy Statement


Varex Imaging Corporation will hold its 2025 Annual Meeting of Stockholders virtually on February 13, 2025, to vote on director elections, executive compensation, and other corporate matters.

Worse than expectedThe company's revenue decreased by 9% compared to the previous fiscal year.The company experienced a GAAP net loss of $48 million, or $(1.17) per diluted share.

Summary

  • Varex Imaging Corporation will host its 2025 Annual Meeting of Stockholders on February 13, 2025, as a virtual meeting.
  • Stockholders will vote to elect seven directors for a one-year term, approve executive compensation on an advisory basis, and decide on the frequency of executive compensation advisory votes.
  • The meeting will also include a vote to approve the amended 2017 Employee Stock Purchase Plan (ESPP), which seeks to increase the number of shares available for issuance by 900,000.
  • Additionally, stockholders will vote on amending the company's Certificate of Incorporation to limit officer liability and ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2025.
  • The record date for determining stockholders eligible to vote is December 16, 2024.
  • The Board recommends voting 'For' all director nominees, the advisory vote on executive compensation, the amended ESPP, the amendment to the Certificate of Incorporation, and the ratification of Deloitte.

Sentiment

Score: 5

Explanation: The document is largely factual and procedural, outlining the agenda and proposals for the annual meeting. While there are some negative financial results mentioned, the overall tone is neutral and focused on corporate governance.

Positives

  • The Board is committed to strong corporate governance, with policies and practices designed to represent the interests of all stockholders.
  • The Board has an independent non-employee director as Chair, and the roles of Chair and Chief Executive Officer are separated.
  • The Board is committed to inclusiveness and diversity, with more than 50% of the Board being diverse.
  • The company has stock ownership guidelines for directors and executive officers to align their interests with those of stockholders.
  • The company has a Compensation Recovery Policy to recover certain cash and equity incentive payments made to executives in the event of a restatement of financial statements.

Risks

  • The document mentions operational, economic, financial, legal, regulatory, and competitive risks faced by the company.
  • The company is exposed to cybersecurity threats, and while they have a risk-based cybersecurity program, there is always a risk of incidents.
  • The company's sales in China were down due to the Chinese government's anti-corruption campaign targeted at the healthcare industry.

Future Outlook

The company remains focused on executing its long-term strategy in China and supports the government's efforts to improve the overall healthcare infrastructure.

Management Comments

  • The Compensation Committee believes that attracting, motivating, and retaining a team of high-performing executives is critical to advancing the interests of stockholders.
  • The Board believes that holding the annual meeting of stockholders in a virtual format provides the opportunity for participation by a broader group of stockholders and reduces the costs associated with planning, holding, and arranging logistics for in-person meeting proceedings.

Industry Context

The company competes in the healthcare equipment and supplies, life sciences tools and services, and electronic equipment instruments and components industries.

Comparison to Industry Standards

  • The Compensation Committee uses a compensation peer group to monitor the compensation practices of our primary competitors for executive talent.
  • The peer group includes companies such as Accuray Incorporated, Lantheus Holdings, Inc., and OSI Systems, Inc.
  • At the time the peer group was selected, Varex had annual revenue above the median and market capitalization below the median of the peer group.

Stakeholder Impact

  • The proposals to be voted on at the Annual Meeting will impact stockholders, employees, and other stakeholders.
  • The election of directors will determine the leadership of the company.
  • The advisory vote on executive compensation will provide stockholders with an opportunity to express their views on the company's pay practices.
  • The approval of the amended ESPP will provide employees with an opportunity to purchase shares of the company's stock at a discount.
  • The amendment to the Certificate of Incorporation to limit officer liability is intended to attract and retain top talent.

Next Steps

  • Stockholders are encouraged to vote their shares as soon as possible.
  • The company will announce preliminary results at the Annual Meeting and final results in a Current Report on Form 8-K.

Key Dates

DateDescription
December 16, 2024Record date for determining stockholders entitled to vote at the Annual Meeting
December 30, 2024Approximate date of mailing or emailing the Notice of Internet Availability of Proxy Materials
February 12, 2025Deadline for submitting proxies via telephone or Internet (11:59 p.m. Eastern Time)
February 13, 2025Date of the 2025 Annual Meeting of Stockholders (4:30 p.m. Mountain Time)
September 1, 2025Deadline for submitting stockholder proposals for inclusion in the 2026 proxy statement
October 16, 2025Earliest date for delivering notice of stockholder proposals to be raised from the floor of the 2026 Annual Meeting
November 15, 2025Latest date for delivering notice of stockholder proposals to be raised from the floor of the 2026 Annual Meeting

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Employee Stock Purchase Plan, Corporate Governance, Deloitte, Officer Liability, Varex Imaging

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.